Tonelli Michele, Boido Vito, Canu Caterina, Sparatore Anna, Sparatore Fabio, Paneni Maria Silvia, Fermeglia Maurizio, Pricl Sabrina, La Colla Paolo, Casula Laura, Ibba Cristina, Collu David, Loddo Roberta
Dipartimento di Scienze Farmaceutiche, Università di Genova, Viale Benedetto XV 3, 16132 Genova, Italy.
Bioorg Med Chem. 2008 Sep 15;16(18):8447-65. doi: 10.1016/j.bmc.2008.08.028. Epub 2008 Aug 15.
Eighty-five arylazoenamines, characterized by different types of aryl and basic moieties, have been synthesized and evaluated in cell-based assays for cytotoxicity and antiviral activity against a panel of ten RNA and DNA viruses. The most commonly affected viruses were, in decreasing order, CVB-2, RSV, BVDV, YFV, and Sb-1; the remaining viruses were either not affected (HIV-1, VSV, and VV) or susceptible only to a very few compounds (Reo-1 and HSV-1). Thirty-five compounds exhibited high activity, with EC(50) in the range 0.8-10 microM, and other 28 compounds had EC(50) between 11 and 30 microM, thus indicating that the arylazoenamine molecular pattern is an interesting novel pharmacophore for antiviral agents against ssRNA viruses. Moreover, some compounds (as 28, 32, 42, and 53) appear of high interest, being devoid of toxicity on the human MT-4 cells (CC(50)>100 microM). A ligand-based computational approach was employed to identify highly predictive pharmacophore models for the most frequently affected viruses CVB-2, RSV, and BVDV. These models should allow the design of second generation of more potent inhibitors of these human and veterinary pathogens.
已合成了85种芳基偶氮烯胺,其特征在于具有不同类型的芳基和碱性部分,并在基于细胞的试验中对其针对一组10种RNA和DNA病毒的细胞毒性和抗病毒活性进行了评估。受影响最常见的病毒依次为CVB - 2、呼吸道合胞病毒(RSV)、牛病毒性腹泻病毒(BVDV)、黄热病病毒(YFV)和Sb - 1;其余病毒要么未受影响(HIV - 1、水疱性口炎病毒(VSV)和痘苗病毒(VV)),要么仅对极少数化合物敏感(呼肠孤病毒1型(Reo - 1)和单纯疱疹病毒1型(HSV - 1))。35种化合物表现出高活性,半数有效浓度(EC(50))在0.8 - 10微摩尔范围内,另外28种化合物的EC(50)在11至30微摩尔之间,这表明芳基偶氮烯胺分子模式是一种针对单链RNA病毒的抗病毒剂的有趣新型药效基团。此外,一些化合物(如28、32、42和53)显得极具吸引力,因为它们对人MT - 4细胞无毒性(半数细胞毒性浓度(CC(50)>100微摩尔))。采用基于配体的计算方法来识别针对受影响最频繁的病毒CVB - 2、RSV和BVDV的高度预测性药效团模型。这些模型应有助于设计出针对这些人类和兽医病原体的更有效第二代抑制剂。